Skip to main content

Adagene, Inc. (ADAG)

NASDAQ: ADAG · IEX Real-Time Price · USD
14.70 -0.52 (-3.42%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap630.12M
Revenue (ttm)1.75M
Net Income (ttm)n/a
Shares Out43.58M
EPS (ttm)-2.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,784
Open14.63
Previous Close15.22
Day's Range14.24 - 14.70
52-Week Range11.11 - 31.83
Betan/a
Analystsn/a
Price Target33.89 (+130.5%)
Est. Earnings Daten/a

About ADAG

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of variou...

IndustryBiotechnology
IPO DateFeb 9, 2021
Employees198
Stock ExchangeNASDAQ
Ticker SymbolADAG
Full Company Profile

Financial Performance

In 2020, Adagene's revenue was $700,913, an increase of 46.02% compared to the previous year's $480,000. Losses were -$42.40 million, 158.0% more than in 2019.

Financial Statements

News

Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming...

2 weeks ago - GlobeNewsWire

Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

- Established three clinical collaborations with Merck to conduct global combination trials  with pembrolizumab for three clinical-stage oncology candidates -

3 weeks ago - GlobeNewsWire

Adagene Inks Third Cancer Trial Collaboration With Merck

Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansio...

Other symbols:MRK
1 month ago - Benzinga

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combina...

Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for patients with advanced or metastatic solid and/or hematological malignancies Collaboration to evaluate NEO...

1 month ago - GlobeNewsWire

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory B...

- Global immuno-oncology experts bring decades of experience to advance company's transformative research and development pipeline - - Global immuno-oncology experts bring decades of experience to advan...

1 month ago - GlobeNewsWire

Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors

Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  The agreement includes two clinical studies to evaluate Adagene's anti-C...

1 month ago - Benzinga

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (AD...

Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pembrolizumab) for patients with advanced/metastatic s...

1 month ago - GlobeNewsWire

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

SAN FRANCISCO and SUZHOU, China, July 07, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disc...

2 months ago - GlobeNewsWire

Adagene Announces Inclusion in FTSE Russell Indexes

SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) --  Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...

3 months ago - GlobeNewsWire

Adagene to Present at Upcoming Investor Conferences

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...

3 months ago - GlobeNewsWire

Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual ...

-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement

4 months ago - GlobeNewsWire

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Researc...

SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...

5 months ago - GlobeNewsWire

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD137 and two anti-CTLA-4 programs- -Advanced five discovery pro...

5 months ago - GlobeNewsWire

Adagene Announces Clinical Advancement for ADG116

-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial-  -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global ex...

5 months ago - GlobeNewsWire

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

SAFEbody technology enables precision masking of antibodies for enhanced safety SAFEbody technology enables precision masking of antibodies for enhanced safety

6 months ago - GlobeNewsWire

Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disco...

7 months ago - GlobeNewsWire

Adagene Inc. Announces Pricing of Initial Public Offering

SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...

7 months ago - GlobeNewsWire

Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate T...

Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s SAFEbody™ technology platform...

7 months ago - Business Wire

Chinese cancer biotech Adagene files for a $125 million US IPO

Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering.

8 months ago - NASDAQ

Adagene IPO Registration Document (S-1)

Adagene, Inc. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC

News briefing: AbbVie selects first target for Dragonfly partnership; Cognito nets BDD for Alzheimer's treatment device

Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment, the compa...

8 months ago - Endpoints News

Adagene Achieves CAR-T Collaboration Milestone

Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.

8 months ago - Contract Pharma